CN103623294B - A kind of preparation method for the treatment of Barrett syndrome medicine - Google Patents
A kind of preparation method for the treatment of Barrett syndrome medicine Download PDFInfo
- Publication number
- CN103623294B CN103623294B CN201310107708.2A CN201310107708A CN103623294B CN 103623294 B CN103623294 B CN 103623294B CN 201310107708 A CN201310107708 A CN 201310107708A CN 103623294 B CN103623294 B CN 103623294B
- Authority
- CN
- China
- Prior art keywords
- parts
- brown
- parched
- fructus
- caulis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 208000023514 Barrett esophagus Diseases 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 238000011282 treatment Methods 0.000 title abstract description 19
- 235000004072 Ocimum sanctum Nutrition 0.000 claims abstract description 19
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 239000000341 volatile oil Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 6
- 238000001556 precipitation Methods 0.000 claims abstract description 4
- 240000002837 Ocimum tenuiflorum Species 0.000 claims abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 15
- 238000001035 drying Methods 0.000 abstract description 4
- 239000000284 extract Substances 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 description 18
- 244000136948 Ocimum sanctum Species 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 15
- 210000003238 esophagus Anatomy 0.000 description 11
- 210000000981 epithelium Anatomy 0.000 description 9
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 7
- 208000000689 peptic esophagitis Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000008765 Sciatica Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 2
- 229960005132 cisapride Drugs 0.000 description 2
- 235000021270 cold food Nutrition 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 235000021268 hot food Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001370 mediastinum Anatomy 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 2
- 229960004291 sucralfate Drugs 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 244000144706 Aeschynomene indica Species 0.000 description 1
- 235000004051 Aeschynomene indica Nutrition 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000244987 Daiswa polyphylla Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000142952 Hamamelidaceae Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000302544 Luffa aegyptiaca Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 240000005498 Setaria italica Species 0.000 description 1
- 244000290970 Tetrapanax papyrifer Species 0.000 description 1
- 241000983344 Trachelospermum jasminoides Species 0.000 description 1
- 240000000377 Tussilago farfara Species 0.000 description 1
- 235000004869 Tussilago farfara Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of medicine for the treatment of Barrett syndrome, to solve the treatment problem of Barrett syndrome.It is characterized in that being prepared from by the crude drug of following weight proportion: Semen Litchi, holy basil, Poria, Pericarpium Citri Reticulatae, Folium Aeschynomense indicae, Caulis Trachelospermi, Radix Puerariae, Rhizoma Paridis, Retinervus Luffae Fructus, Caulis Exbucklandiae Populneae, Fructus Hordei Germinatus (parched to brown), Fructus Setariae Germinatus (parched to brown).Its preparation method comprises: (1) by Radix Puerariae, holy basil, Folium Aeschynomense indicae coarse powder extract volatile oil for subsequent use; (2) Fructus Setariae Germinatus (parched to brown) is ground into fine powder for subsequent use; (3) Semen Litchi, Poria, Pericarpium Citri Reticulatae, Caulis Trachelospermi, Retinervus Luffae Fructus, Rhizoma Paridis, Caulis Exbucklandiae Populneae, Fructus Hordei Germinatus (parched to brown) water extract-alcohol precipitation, obtains just material after drying; (4) sprayed into by volatile oil in first material, add the mixing of Fructus Setariae Germinatus (parched to brown) fine powder, cross 60 mesh sieves, tabletting forms.Clinical trial certificate, the present invention treats Barrett syndrome and has good effect and the higher feature of safety, clinic application, promotes.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of preparation method for the treatment of the medicine of Barrett syndrome.
Background technology
Barrett syndrome (Barrett Syndrome), also known as Barrett ulcer, refer to lower esophageal mucosa replace by stomach columnar epithelium.First nineteen fifty is described by Barrett, therefore claims Barrett syndrome.Intrinsic can be congenital, but is often secondary to reflux esophagitis, and the basis of stomach-esophageal reflux occurs esophagitis and ulcer.Its pathological characteristic is that acid nonfast squamous epithelial cancer is damaged, and acidproof columnar epithelium regeneration also involves distal esophagus to vertical spread gradually.Ulcer can penetrate esophageal wall, and make mediastinum tissue's fibrosis and lymphadenitis occurs, if blood vessel is damaged, cause bleeding, mediastinum and pleura can have purulent lesion.Microscopy mucosal inner layer has the columnar epithelial cell exception of atypia and hypertrophy.
The clinical treatment for Barrett syndrome is how identical with reflux esophagitis, as application mucosa protective agent sucralfate, gives H2-receptor blocking agent or proton pump inhibitor and dynamics-promoting medicine prepulsid simultaneously.But in fact clinical effectiveness not obvious.Its reason is that Barrett syndrome is not identical with reflux esophagitis pathomechanism.The pathophysiological basis of reflux esophagitis morbidity is esophagus and stomach motion-promotion force obstacle, comprises the motor function of EB, LES function and gastric motor dysfunction, causes burn feeling after breastbone.Reflux esophagitis is the risk factor of Barrett syndrome, but still some case even basis of not reflux esophagitis, and only shows stomach columnar epithelium lined esophagus and divide a word with a hyphen at the end of a line, and then produces ulcer.
And Chinese traditional treatment is also how the two treatment to be obscured mutually, how to start with from hyperactive liver-QI attacking the stomach, syndrome of liver-stomach heat, deficiency of YIN of the spleen and stomach, treatment can improve digestive tract power, solve the symptoms such as gastralgia belch, but fundamentally can not solve " stomach columnar epithelium lined esophagus is divided a word with a hyphen at the end of a line " this pathological factor, so once take food after hot and cold food, particularly acidic food, can recur again.So current Barrett syndrome patient, often carries out surgical operation because of showing effect frequently, partial row surgical excision that stomach columnar epithelium lined esophagus is divided a word with a hyphen at the end of a line.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of curative effect to affirm and effectively prevents the preparation method of the medicine of the treatment Barrett syndrome recurred.
The technical scheme that the present invention solves its technical problem is: a kind of pharmaceutical composition for the treatment of Barrett syndrome, it is characterized in that being prepared from by the crude drug of following weight proportion: Semen Litchi 10 ~ 30 parts, holy basil 6 ~ 12 parts, 3 ~ 10 parts, Poria, Pericarpium Citri Reticulatae 6 ~ 12 parts, Folium Aeschynomense indicae 3 ~ 10 parts, Caulis Trachelospermi 6 ~ 12 parts, Radix Puerariae 6 ~ 12 parts, Rhizoma Paridis 6 ~ 12 parts, Retinervus Luffae Fructus 6 ~ 12 parts, Caulis Exbucklandiae Populneae 1 ~ 5 part, Fructus Hordei Germinatus (parched to brown) 3 ~ 10 parts, Fructus Setariae Germinatus (parched to brown) 10 ~ 25 parts.
Said medicine can be prepared from by following method:
(1) Radix Puerariae, holy basil, Folium Aeschynomense indicae coarse powder are extracted volatile oil with vapor distillation respectively, and mixing for standby use after collecting;
(2) Fructus Setariae Germinatus (parched to brown), Fructus Hordei Germinatus (parched to brown) are pulverized 150 mesh sieves, and become fine powder for subsequent use;
(3) Semen Litchi, Poria, Pericarpium Citri Reticulatae, Caulis Trachelospermi, Retinervus Luffae Fructus, Rhizoma Paridis, Caulis Exbucklandiae Populneae mixing add 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, leave standstill; Then in decocting liquid, add the ethanol of 95% of 3 ~ 4 times of medicinal liquids, leave standstill 15 minutes, then with 3000rpm/min centrifugal 20 minutes, get precipitation, spraying dry, draw just material;
(4) sprayed into by gained volatile oil in step 1 during step 3 gained just expects, add gained fine powder mixing in step 2, cross 60 mesh sieves, tabletting forms.
Wherein said: Semen Litchi is the dry mature seed of sapindaceous plant Fructus Litchi Litchi chinensis Sonn..Sweet, the micro-hardship of nature and flavor, temperature.Return liver, kidney channel.Merit can promoting QI to circulate and dispersing the agglomeration of the pathogens, cold-dispelling pain-relieving.
Holy basil is the whole herb with root of labiate holy basil Ocimum sanctum L..Merit can pain relieving; Relieving asthma.Main headache; Asthma.
Poria is On Polyporaceae Poria Poriacocos(Schw.) Wolf sclerotium white part.Nature and flavor are sweet, light, flat.GUIXIN, lung, spleen, kidney channel.Merit can promoting diuresis to eliminate damp pathogen, and spleen invigorating, reduces phlegm, mind tranquilizing and the heart calming.
Pericarpium Citri Reticulatae is the dry mature skin of rutaceae orange Citrus reticulata Blanco and variety thereof.Nature and flavor are bitter, pungent, temperature.Return lung, spleen channel.Merit can regulating qi-flowing for strengthening spleen, drying dampness to eliminate phlegm.
Folium Aeschynomense indicae is the stem pith of leguminous plant Herba Aeschynonenes Indicae stem Aeschynomene indica L..Nature and flavor are bitter, flat.Attach to the lung and stomach meridians.Heat clearing away, diuresis, lactogenesis, improving eyesight.
Caulis Trachelospermi is the dry zone leaf rattan of apocynaceae plant trachelospermum jasminoide Trachelospermum jasminoides (Lindl.) Lem..Hardship, is slightly cold.GUIXIN, liver, kidney channel.Merit can dispelling wind and removing obstruction in the collateral, and removing heat from blood is subsided a swelling.
Radix Puerariae, Radix Puerariae is the root of leguminous plant Pachyrhizua angulatus.Sweet, pungent, flat.Enter spleen, stomach warp.Merit can be induced sweat, rash, and relaxing muscles and tendons promotes the production of body fluid, antidiarrheal.
Rhizoma Paridis is the rhizome of liliaceous plant Rhizoma Paridis Paris polyphylla Sm..Hardship, is slightly cold.Enter Liver Channel.Merit can heat-clearing and toxic substances removing, detumescence, spasmolytic.
Retinervus Luffae Fructus is the vascular bundle of the dry mature fruit of cucurbitaceous plant Fructus Luffae Luffa cylindrica (L.) Roem..Sweet, flat.Return lung, stomach, Liver Channel.Merit can dredging collateral, invigorates blood circulation, dispels the wind.
Caulis Exbucklandiae Populneae is the stem of Hamamelidaceae Plants Horse hoof lotus.Sour and astringent, temperature.Merit can relaxing muscles and tendons to promote blood circulation, activating collaterals to relieve pain.Treating rheumatic arthritis, sciatica.
Fructus Hordei Germinatus (parched to brown), for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L. is through drying of germinateing, fries to burnt brown according to frying method, cooling, sieve dedust bits.Nature and flavor are sweet, flat.Return spleen, stomach warp.Merit can promote qi circulation digestion promoting, and spleen benefiting and stimulating the appetite, moves back newborn relieving distension.
Fructus Setariae Germinatus (parched to brown), for the mature fruit of grass foxtail millet Setaria italica (L.) Beauv. is through drying of germinateing, fries to burnt brown according to frying method.Nature and flavor are sweet, temperature.Return spleen, stomach warp.Merit can help digestion and in, spleen benefiting and stimulating the appetite.
Composition principle: Barrett syndrome refer to lower esophageal mucosa replace by stomach columnar epithelium.The current traditional Chinese medical science is how identical with reflux esophagitis for the treatment of Barrett syndrome, how to start with from hyperactive liver-QI attacking the stomach, syndrome of liver-stomach heat, deficiency of YIN of the spleen and stomach, treatment can improve digestive tract power, solve the symptoms such as gastralgia belch, but fundamentally can not solve " stomach columnar epithelium lined esophagus is divided a word with a hyphen at the end of a line " this pathological factor, so once take food after hot and cold food, particularly acidic food, can recur again.Applicant weighs checking through repetition test and draws prescription disclosed by the invention.
Compared with prior art, the present invention has following characteristics.
1, prescription is unique: inventor thinks that primary disease is that expectorant folder blood stasis forms, phlegm and blood stasis, and glue work, for suffering from, should be invigorated blood circulation, eliminate the phlegm, eliminating stagnation, dredging collateral go forward side by side, can improve the paraplasm pathology present situation of Barrett syndrome mucosa; Avoid the medicine using the liver heat removing circulation of qi promoting such as Radix Bupleuri, Radix Curcumae, Radix Gentianae in side, its reason is that such medicine can not improve mucosa paraplasm, on the contrary easy cold and cool catharsis too impairment of YANG impairment of YIN; So get Semen Litchi in side, holy basil is monarch, Semen Litchi can enter gastral cavilty esophagus, promoting QI to circulate and dispersing the agglomeration of the pathogens, cold-dispelling pain-relieving; Holy basil originally effect is that pain relieving is relievingd asthma, main headache, asthma, but applicant's cell culture experiments confirms, the quintessence oil of holy basil can protect acid nonfast squamous cell, prevents stomach columnar epithelium from regenerating and divides a word with a hyphen at the end of a line; Semen Litchi, both holy basils coordinate, and improve digestive tract power on the one hand, solve the symptoms such as gastralgia belch, can protect esophagus hypomere mucosa on the other hand by holy basil by current the faling apart of temperature; Semen Litchi can increase the curative effect of holy basil this respect.
2, blood system medicine Caulis Trachelospermi, Retinervus Luffae Fructus, Caulis Exbucklandiae Populneae are except removing heat from blood and promoting blood circulation effect, all have dredging collateral effect, a medicine multiple-effect, contribute to reducing medicament categories and consumption, do not increase Liver and kidney burden; And Caulis Exbucklandiae Populneae is used for rheumatic arthritis, sciatica originally, but applicant tests discovery, add a small amount of Caulis Exbucklandiae Populneae and contribute to sending down the abnormal ascending QI, and this kind of sedimentation is not by mechanism of qi effect, but from blood system, from channels, contribute to preventing stomach columnar epithelium lined esophagus from dividing a word with a hyphen at the end of a line.
3, manage spleen with removing dampness, cure the disease and ask its source, so prescription Poria of the present invention, Pericarpium Citri Reticulatae invigorating spleen to remove dampness.
4, Radix Puerariae relaxing muscles and tendons, Rhizoma Paridis spasmolytic, Caulis Exbucklandiae Populneae are capable alters active, and three medicine combineds effect, in the hope of alleviating esophagus hypomere smooth muscle spasm, reduce Weishang mouth tractive tension force, contribute to alleviating esophageal regurgitation.
5, prescription Kai Heyou road, gets Folium Aeschynomense indicae in we, and Folium Aeschynomense indicae is different from Medulla Tetrapanacis (Araliaceae rice-paper plant), Medulla Tetrapanacis is recorded from " book on Chinese herbal medicine converges and says ": " deficiency of both YIN and YANG person forbidding ", and chief reason is that the dynamics of Medulla Tetrapanacis folding is comparatively large, and empty person uses, then easily dissipation gas is cloudy, and the lightly seasoned gas of Folium Aeschynomense indicae is clear, its gas is clear, falls also, it is lightly seasoned, open also, Herba indigoferae Pseudotinctoriae then has mechanism of qi and opens entire merit, the anxiety of the moon and nothing is felt frustrated; And the use of Fructus Hordei Germinatus (parched to brown) and Fructus Setariae Germinatus (parched to brown), be also consider from interior tonifying the spleen gas; We avoid using the antiacid medicines such as Os Sepiae simultaneously, by " with extensively treating acid ".
6, medicine material consumption of the present invention is groped to sum up to draw through inventor in a large number, each raw material dosage is for all to have good curative effect in following weight parts scope: Semen Litchi amount is larger, inventor studies discovery, only has escalated dose Semen Litchi side that holy basil drug effect row can be helped to fall apart; And the dosage of Caulis Exbucklandiae Populneae is very little, reason be the Caulis Exbucklandiae Populneae of middle heavy dose for promoting blood circulation and stopping pain, and get Caulis Exbucklandiae Populneae effect in we and be active sending down the abnormal ascending QI, without the need to heavy dose, slightly.
7, Tabules, taking convenience, easy to carry, compliance is good, is convenient to the consolidation of the course for the treatment of; And preparation method is unique, inventor repeatedly animal experiment research finds, holy basil extracts volatile oil and enters decoct effect quite, but side effect obviously reduces; And Fructus Hordei Germinatus (parched to brown), Fructus Setariae Germinatus (parched to brown) enter capsule without the direct flour of decoction, effect has three: 1. can tonifying the spleen gas; 2. the use of adjuvant is decreased; 3. can wrap up other drug, decrease the stimulation of other drug to gastrointestinal.
Detailed description of the invention
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, crude drug weight proportion: Semen Litchi 10 parts, holy basil 6 parts, 3 parts, Poria, Pericarpium Citri Reticulatae 6 parts, Folium Aeschynomense indicae 3 parts, Caulis Trachelospermi 6 parts, Radix Puerariae 6 parts, Rhizoma Paridis 6 parts, Retinervus Luffae Fructus 6 parts, Caulis Exbucklandiae Populneae 1 part, Fructus Hordei Germinatus (parched to brown) 3 parts, Fructus Setariae Germinatus (parched to brown) 10 parts.
Embodiment 2, crude drug weight proportion: Semen Litchi 20 parts, holy basil 10 parts, 6 parts, Poria, Pericarpium Citri Reticulatae 10 parts, Folium Aeschynomense indicae 6 parts, Caulis Trachelospermi 10 parts, Radix Puerariae 10 parts, Rhizoma Paridis 10 parts, Retinervus Luffae Fructus 10 parts, Caulis Exbucklandiae Populneae 2 parts, Fructus Hordei Germinatus (parched to brown) 6 parts, Fructus Setariae Germinatus (parched to brown) 20 parts.
Embodiment 3, crude drug weight proportion: Semen Litchi 30 parts, holy basil 12 parts, 10 parts, Poria, Pericarpium Citri Reticulatae 12 parts, Folium Aeschynomense indicae 10 parts, Caulis Trachelospermi 12 parts, Radix Puerariae 12 parts, Rhizoma Paridis 12 parts, Retinervus Luffae Fructus 12 parts, Caulis Exbucklandiae Populneae 5 parts, Fructus Hordei Germinatus (parched to brown) 10 parts, Fructus Setariae Germinatus (parched to brown) 25 parts.
The Chinese medicine of embodiment 1 ~ 3 can be prepared from by following method:
(1) Radix Puerariae, holy basil, Folium Aeschynomense indicae coarse powder are extracted volatile oil with vapor distillation respectively, and mixing for standby use after collecting;
(2) Fructus Setariae Germinatus (parched to brown), Fructus Hordei Germinatus (parched to brown) are pulverized 150 mesh sieves, and become fine powder for subsequent use;
(3) Semen Litchi, Poria, Pericarpium Citri Reticulatae, Caulis Trachelospermi, Retinervus Luffae Fructus, Rhizoma Paridis, Caulis Exbucklandiae Populneae mixing add 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, leave standstill; Then in decocting liquid, add the ethanol of 95% of 3 ~ 4 times of medicinal liquids, leave standstill 15 minutes, then with 3000rpm/min centrifugal 20 minutes, get precipitation, spraying dry, draw just material;
(4) sprayed into by gained volatile oil in step 1 during step 3 gained just expects, add gained fine powder mixing in step 2, cross 60 mesh sieves, tabletting forms.
Can set tablet monolithic dosage is 0.5g.
The efficient combination of said medicine, coordinates mutually, invigorates blood circulation, eliminates the phlegm, eliminating stagnation, dredging collateral, effectively reach the object for the treatment of Barrett syndrome, and side effect is less.The above results is clinical data sufficient proof, and interrelated data is as follows.
1 object and method.
1.1 object.
1.1.1 case selection: in March, a 2006 ~ 2012 year December is diagnosed as Barrett syndrome 48 example, is outpatient, is divided into matched group and experimental group.Matched group 20 example, age 45 ~ 74(57.32 ± 12.71) year; Experimental group 28 example, age 46 ~ 78(63.48 ± 13.11) year.Compare in sex, age, the state of an illness before three groups of patient treatments, no significant difference (P>0.05), has comparability.
1.1.2 diagnostic criteria: with reference to " Digestive System Department diagnosis of disease guide " (the 2nd edition), except the hypomere retrosternal pain of recurrent exerbation and burn feeling, the visible esophageal wall of x-ray inspection is isolatism crateriform ulcer or niche, far-end gauffer apart from volcanic crater disappears or atypical gauffer; spasm above pathological changes, narrow due to edema; Esophagoscopy visible crateriform ulcer stove, mucosa gauffer owe clear, inflammation edema, hemorrhage, white macula.Examination of castoff cells is without malignant cell.
1.2 method.
1.2.1 Therapeutic Method: matched group takes symptomatic treatment, adopt sucralfate and dynamics-promoting medicine prepulsid oral.Experimental group is oral with gained tablet in the embodiment of the present invention 3,2g/ time, 2 times/d.It within 1 month, was 1 course for the treatment of.
1.2.2 criterion of therapeutical effect: with reference to " Digestive System Department diagnosis of disease guide ", recovery from illness: clinical symptoms, sign disappear; Effective: clinical symptoms, sign turn for the better by and large; Effective: clinical symptoms, sign alleviate; Invalid: clinical symptoms, sign are unchanged.
1.2.3 statistical analysis: SPSS 13.0 carries out statistical analysis.Measurement data t checks, enumeration data chi-square criterion.
2 results.
2.1 Clinical efficacy comparisons: each group cure-remarkable-effectiveness rate is respectively: matched group 50.00%, experimental group 78.57%, experimental group cure-remarkable-effectiveness rate is apparently higher than matched group (P<0.05).
2.2 patient's esophagus hypomere mucosal inner layer microscopy results: compare before and after treatment, taking a turn for the better appears in matched group 30.00%, and taking a turn for the better appears in experimental group 67.86%, and experimental group cure-remarkable-effectiveness rate is apparently higher than matched group (P<0.05).
2.3 relapse rates compare: follow up a case by regular visits to half a year, and in half a year, each group relapse rate is: matched group 85.00%, experimental group 39.29%, the relapse rate of experimental group is starkly lower than matched group (P<0.05).
2.4 3 groups of adverse reactions of patients incidence rates compare: untoward reaction totally 4 examples appear in matched group, and incidence rate is 20.00%; There are untoward reaction totally 3 examples in experimental group, incidence rate is 10.71%.Above-mentioned untoward reaction is all slight, is temporary response.The adverse reaction rate of experimental group is starkly lower than matched group (P<0.05).
3. conclusion.
This result of study shows, take experimental group cure-remarkable-effectiveness rate of the present invention apparently higher than matched group, and and the incidence rate of relapse rate and untoward reaction lower than matched group, illustrate that the present invention has the advantage that untoward reaction is comparatively light, safety is higher in treatment Barrett syndrome.
Claims (1)
1. treat the preparation method of Barrett syndrome medicine for one kind, it is characterized in that: described medicine is prepared from by following bulk drugs: Semen Litchi 10 ~ 30 parts, holy basil 6 ~ 12 parts, 3 ~ 10 parts, Poria, Pericarpium Citri Reticulatae 6 ~ 12 parts, Folium Aeschynomense indicae 3 ~ 10 parts, Caulis Trachelospermi 6 ~ 12 parts, Radix Puerariae 6 ~ 12 parts, Rhizoma Paridis 6 ~ 12 parts, Retinervus Luffae Fructus 6 ~ 12 parts, Caulis Exbucklandiae Populneae 1 ~ 5 part, Fructus Hordei Germinatus (parched to brown) 3 ~ 10 parts, Fructus Setariae Germinatus (parched to brown) 10 ~ 25 parts, concrete preparation method is made up of following steps:
(1) Radix Puerariae, holy basil, Folium Aeschynomense indicae coarse powder are extracted volatile oil with vapor distillation respectively, and mixing for standby use after collecting;
(2) Fructus Hordei Germinatus (parched to brown), Fructus Setariae Germinatus (parched to brown) are pulverized 150 mesh sieves, and become fine powder for subsequent use;
(3) Semen Litchi, Poria, Pericarpium Citri Reticulatae, Caulis Trachelospermi, Retinervus Luffae Fructus, Rhizoma Paridis, Caulis Exbucklandiae Populneae mixing are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, leave standstill; Then in decocting liquid, add the ethanol of 95% of 3 ~ 4 times of medicinal liquids, leave standstill 15 minutes, then with 3000rpm/min centrifugal 20 minutes, get precipitation spraying dry, obtain just material;
(4) sprayed into by gained volatile oil in step 1 during step 3 gained just expects, then add gained fine powder mixing in step 2, cross 60 mesh sieves, tabletting forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310107708.2A CN103623294B (en) | 2013-03-31 | 2013-03-31 | A kind of preparation method for the treatment of Barrett syndrome medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310107708.2A CN103623294B (en) | 2013-03-31 | 2013-03-31 | A kind of preparation method for the treatment of Barrett syndrome medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103623294A CN103623294A (en) | 2014-03-12 |
| CN103623294B true CN103623294B (en) | 2015-09-30 |
Family
ID=50204977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310107708.2A Expired - Fee Related CN103623294B (en) | 2013-03-31 | 2013-03-31 | A kind of preparation method for the treatment of Barrett syndrome medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103623294B (en) |
-
2013
- 2013-03-31 CN CN201310107708.2A patent/CN103623294B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103623294A (en) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104523865A (en) | Medicine for treating breast diseases | |
| CN102580000A (en) | Medicament for curing cancer pain and preparation method thereof | |
| CN102302733B (en) | Oral Chinese medicinal composition for treating ovarian cyst | |
| CN103611021B (en) | Be used for the treatment of medicine of Vesica sus domestica inflammation and preparation method thereof | |
| CN101327293B (en) | Capsules for treating peptic ulcer and preparation method thereof | |
| CN104383244A (en) | Traditional Chinese medicine composition for treating esophagus cancer and preparation method of traditional Chinese medicine composition | |
| CN103623294B (en) | A kind of preparation method for the treatment of Barrett syndrome medicine | |
| CN103157042B (en) | Medicament for treating Barrett syndrome | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN101502597B (en) | Medicament for treating stomachache and preparation method thereof | |
| CN103191345B (en) | Postoperative drug for chronic peptic ulcer and esophagitis syndrome | |
| CN104055959A (en) | Traditional Chinese medicine lotion and nursing method for treating gastrointestinal dampness-heat type seborrhoeic dermatitis | |
| CN103191339B (en) | Method for preparing drug for treating pediatric esophageal achalasia | |
| CN103191342B (en) | Method for preparing diaphyseal aclasis nursing substance | |
| CN114886959B (en) | Pharmaceutical composition, preparation and application thereof | |
| CN103191344B (en) | Method for preparing postoperative drug for chronic peptic ulcer and esophagitis syndrome | |
| CN103142898B (en) | Preparation method of medicine used after esophageal achalasia operation | |
| CN101554461B (en) | Medicine for treating psoriasis and preparation method of capsule thereof | |
| CN103191336B (en) | Method for preparing drug for treating esophageal achalasia | |
| CN103191335B (en) | Pharmaceutical composition for treating esophageal achalasia | |
| CN104784651A (en) | Method for preparing pharmaceutical preparation for treating gastric ulcer | |
| CN103191338B (en) | Pharmaceutical composition for treating pediatric esophageal achalasia | |
| CN103157040A (en) | Pharmaceutical composition for treating multiple osteoenchondroma | |
| CN103223130A (en) | Traditional Chinese medicinal composition for treating prostatic hyperplasia and preparation method of preparation thereof | |
| CN103191340A (en) | Drug for nursing osteochondroma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: YANG XIUFANG XING JINSHAN Effective date: 20150820 Owner name: MAO CONGJUN Free format text: FORMER OWNER: WANG LING Effective date: 20150820 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Mao Congjun Inventor after: Yang Xiufang Inventor after: Xing Jinshan Inventor before: Wang Ling |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG LING TO: MAO CONGJUN YANG XIUFANG XING JINSHAN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150820 Address after: Third people's Hospital of Shandong, Laizhou Province, 298 Gulou Street, Shandong, Yantai, Laizhou 261400, China Applicant after: Mao Congjun Applicant after: Yang Xiufang Applicant after: Xing Jinshan Address before: 276826 Rizhao People's Hospital, 126 Tai'an Road, Shandong, Rizhao City, China Applicant before: Wang Ling |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150930 Termination date: 20160331 |